In the present study, the effects of pretreatment with Pravastatin and Gemfibrozil on intestinal and hepatic microcirculation during sepsis were investigated. Dysregulated intestinal and hepatic oxygenation play a central role in the pathomechanism of sepsis. Stabilization and improvement of intestinal and hepatic microcirculatory oxygenation are essential for healing and survival in sepsis17. Therefore, it should be clarified whether drug-induced enhancement of microcirculatory oxygenation represents a new therapeutic approach for the treatment of dysregulated oxygenation in the intestine and liver. Furthermore, to answer the question of whether and to what extent the PPAR-α receptor is involved in mediating Pravastatin and Gemfibrozil action and whether a dose-response relationship exists for Gemfibrozil. Experiments were performed in WISTAR rats in which abdominal sepsis was induced by CASP-surgery. The results of this study show that postcapillary oxygenation of the intestine and liver worsens under septic conditions and that pretreatment with Pravastatin and Gemfibrozil reverses this worsening. The effect of Gemfibrozil is mediated in a concentration-independent manner. In contrast to the septic setting, Pravastatin and Gemfibrozil show a negative effect on intestinal microcirculation under non-septic conditions, and the hepatic microcirculation remains stable under both drugs. A mediation of the effect of both drugs via the PPAR-α receptor could not be confirmed. These results support the importance of pretreatment with Pravastatin and Gemfibrozil for future therapies for septic diseases. About clinical practice, further studies should evaluate the use of both drugs in the setting of sepsis, also about the pre-disease profile and complications in the course of the disease.weiterlesen